1. HDL-Mediated Cholesterol Efflux and Plasma Loading Capacities Are Altered in Subjects with Metabolically- but Not Genetically Driven Non-Alcoholic Fatty Liver Disease (NAFLD)
- Author
-
Di Costanzo, A, Ronca, A, D&apos, Erasmo, L, Manfredini, M, Baratta, F, Pastori, D, Di Martino, M, Ceci, F, Angelico, F, Del Ben, M, Pavanello, C, Turri, M, Calabresi, L, Favari, E, and Arca, M
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Medicine (miscellaneous) ,030204 cardiovascular system & hematology ,reverse cholesterol transport (RCT) ,digestive system ,genetic NAFLD ,Article ,General Biochemistry, Genetics and Molecular Biology ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,lcsh:QH301-705.5 ,biology ,urogenital system ,Cholesterol ,Fatty liver ,nutritional and metabolic diseases ,medicine.disease ,digestive system diseases ,metabolic NAFLD ,030104 developmental biology ,Endocrinology ,lcsh:Biology (General) ,ABCG1 ,chemistry ,cholesterol efflux capacity (CEC) ,cholesterol loading capacity (CLC) ,ABCA1 ,cardiovascular system ,biology.protein ,Efflux ,Metabolic syndrome ,Ex vivo ,Lipoprotein - Abstract
Background. Non-alcoholic fatty liver disease (NAFLD) increases the risk of atherosclerosis but this risk may differ between metabolically- vs. genetically-driven NAFLD. High-density lipoprotein (HDL)-mediated cholesterol efflux (CEC) and plasma loading capacity (CLC) are key factors in atherogenesis. Aims. To test whether CEC and CLC differ between metabolically- vs. genetically-determined NAFLD. Methods: CEC and CLC were measured in 19 patients with metabolic NAFLD and wild-type PNPLA3 genotype (Group M), 10 patients with genetic NAFLD carrying M148M PNPLA3 genotype (Group G), and 10 controls PNPLA3 wild-types and without NAFLD. CEC and CLC were measured ex vivo by isotopic and fluorimetric techniques using cellular models. Results: Compared with Group G, Group M showed reduced total CEC (&minus, 18.6%, p <, 0.001) as well as that mediated by cholesterol transporters (&minus, 25.3% ABCA1, &minus, 16.3% ABCG1, 14.8% aqueous diffusion, all p <, 0.04). No difference in CEC was found between Group G and controls. The presence of metabolic syndrome further impaired ABCG1-mediated CEC in Group M. Group M had higher plasma-induced CLC than Group G and controls (p <, 0.001). Conclusions: Metabolically-, but not genetically-, driven NAFLD associates with dysfunctional HDL-meditated CEC and abnormal CLC. These data suggest that the mechanisms of anti-atherogenic protection in metabolic NAFLD are impaired.
- Published
- 2020